Bill Facteau Biography and Net Worth

Director of BioCardia

Bill Facteau was appointed to our board of directors effective October 18, 2023. Mr. Facteau is the President and Chief Executive Officer of Earlens Corporation, which is focused on transforming the hearing aid industry with its novel and proprietary light-based technology, and has served in that capacity since November 2013. Prior to joining Earlens, Mr. Facteau served as President and Chief Executive Officer of Acclarent, the company that created Balloon Sinuplasty. Mr. Facteau previously served as a director on the board of a number of companies, including Acclarent, Aerin Medical, PROCEPT BioRobotics, Neotract, CVI, Cabachon and ExploraMed. Mr. Facteau holds a bachelor’s degree from the University of Connecticut.

What is Bill Facteau's net worth?: The estimated net worth of Bill Facteau is at least $13.91 thousand as of April 23rd, 2025. Mr. Facteau owns 13,123 shares of BioCardia stock worth more than $13,910 as of October 5th. This net worth approximation does not reflect any other investments that Mr. Facteau may own. Learn More about Bill Facteau's net worth.
How do I contact Bill Facteau?: The corporate mailing address for Mr. Facteau and other BioCardia executives is 320 Soquel Way, Sunnyvale, CA, 94085. BioCardia can also be reached via phone at (650) 226-0123 and via email at [email protected]. Learn More on Bill Facteau's contact information.
Has Bill Facteau been buying or selling shares of BioCardia?: Bill Facteau has not been actively trading shares of BioCardia in the last ninety days. Most recently, on Wednesday, April 23rd, Bill Facteau bought 13,123 shares of BioCardia stock. The stock was acquired at an average cost of $1.91 per share, with a total value of $25,064.93. Following the completion of the transaction, the director now directly owns 13,123 shares of the company's stock, valued at $25,064.93. Learn More on Bill Facteau's trading history.
Who are BioCardia's active insiders?: BioCardia's insider roster includes Peter Altman (CEO), Andrew Blank (Director), Andrew Blank (Director), Bill Facteau (Director), Edward Gillis (SVP), and David Mcclung (CFO). Learn More on BioCardia's active insiders.
Are insiders buying or selling shares of BioCardia?: In the last twelve months, BioCardia insiders bought shares 26 times. They purchased a total of 169,900 shares worth more than $162,947.00. The most recent insider tranaction occured on September, 29th when CEO Peter Altman bought 1,000 shares worth more than $1,030.00. Insiders at BioCardia own 17.4% of the company. Learn More about insider trades at BioCardia.
Information on this page was last updated on 9/29/2026.

Bill Facteau Insider Trading History at BioCardia

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
4/23/2025	Buy	13,123	$1.91	$25,064.93	13,123

Bill Facteau Buying and Selling Activity at BioCardia

BioCardia Company Overview

BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. Its lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia. The company is also developing an allogeneic cells therapy platform, which is an investigational culture expanded bone marrow derived mesenchymal cell therapy in Phase I/II trial to treat ischemic heart failure and acute respiratory distress syndrome. In addition, it offers the Helix biotherapeutic delivery system for minimally invasive targeted delivery of biologic agents to the heart; and Morph deflectable guides and sheaths. The company has collaboration agreements with CellProthera in the development of ProtheraCytes, which is currently under Phase II trial for the treatment of acute myocardial infarction. BioCardia, Inc. is based in Sunnyvale, California.

Today's Range

Now: $1.07

$1.04

$1.07

50 Day Range

MA: $1.02

$0.77

$1.25

2 Week Range

Now: $1.07

$0.75

$1.80

Volume

71,901 shs

Average Volume

1,125,218 shs

Market Capitalization

$16.12 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.62